UBS Group
IKT icon

UBS Group’s Inhibikase Therapeutics IKT Stock Holding History

UBS Group’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$383K Buy
228,151
+133,606
+141% +$237K ﹤0.01% 6256
2025
Q4 		$194K Sell
94,545
-41,735
-31% -$66.4K ﹤0.01% 6593
2025
Q3 		$221K Buy
136,280
+97,606
+252% +$169K ﹤0.01% 6620
2025
Q2 		$75.4K Sell
38,674
-6,592
-15% -$12.9K ﹤0.01% 7456
2025
Q1 		$99.1K Buy
45,266
+17,740
+64% +$44.6K ﹤0.01% 7057
2024
Q4 		$89.5K Buy
27,526
+22,653
+465% +$56.5K ﹤0.01% 6941
2024
Q3 		$6.33K Buy
+4,873
New +$6.52K ﹤0.01% 7978
2024
Q2 		– Sell
-3,214
Closed -$6.94K – 9773
2024
Q1 		$6.94K Buy
+3,214
New +$7.09K ﹤0.01% 7425
2023
Q4 		– Sell
-149
Closed -$207 – 9581
2023
Q3 		$207 Buy
+149
New +$334 ﹤0.01% 8703
2023
Q1 		– Sell
-22
Closed -$65 – 9937
2022
Q4 		$65 Sell
22
-1,228
-98% -$4.87K ﹤0.01% 10452
2022
Q3 		$7K Buy
+1,250
New +$6.58K ﹤0.01% 8875
2022
Q2 		– Sell
-852
Closed -$8K – 10597
2022
Q1 		$8K Buy
852
+559
+191% +$4.5K ﹤0.01% 8669
2021
Q4 		$3K Sell
293
-1,132
-79% -$12.5K ﹤0.01% 9659
2021
Q3 		$16K Buy
+1,425
New +$19.3K ﹤0.01% 7417

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

UBS Group's IKT Position: Q1 2026 in Review

UBS Group increased its Inhibikase Therapeutics (IKT) stake by 141% in Q1 2026, buying an estimated $237K and bringing the position to 228,151 shares worth $383K. The position accounts for ﹤0.01% of the portfolio, ranked #6256.

UBS Group first reported a position in IKT in Q3 2021 and has held it in 14 quarters since. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • UBS Group held 228,151 shares of Inhibikase Therapeutics worth $383K as of Q1 2026.
  • UBS Group bought 133,606 Inhibikase Therapeutics shares in Q1 2026, an estimated $237K.
  • Inhibikase Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6256 holding.
  • UBS Group first reported a position in Inhibikase Therapeutics in Q3 2021 and has held it in 14 quarters since.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.